Literature DB >> 721318

Induction of a tumor with greatly increased metastatic growth potential by injection of cells from a low-metastatic H-2 heterozygous tumor cell line into an H-2 incompatible parental strain.

R S Kerbel, R R Twiddy, D M Robertson.   

Abstract

An H-2 heterozygous sarcoma, MDAY, originally induced with methylcholanthrene in an (A X DBA/2)F1 ((H-2a X H-2d) hybrid host was selected for growth in the H-2d homoxygous parental DBA/2 strain by serial intraperitoneal transplantation of ascites tumor cells. An apparent variant, designated MDAY-D2, was obtained which showed the expected loss of the private and public H-2Kk haplotype antigens normally associated with the A strain parent and the original MDAY tumor. Comparison of the original and variant lines revealed a wide variety of a cell surface antigen and receptor differences. Both tumors were found to be highly anaplastic and histologically unclasssifiable. Examination of the two tumor lines growing in vivo revealed a remarkable difference in their metastatic growth potential. The original MDAY line showed little propensity to spread to any organ site, with the occasional exception of liver, after subcutaneous inoculation of (A X DBA/2)F1 mice. In striking contrast, there was a rapid and massive spread of MDAY-D2 to liver, spleen, lungs and kidneys within 12-16 days: liver and spleen could be totally replaced by tumor within 2-3 weeks. These characteristics were observed in both (A X DBA/2)F1 and DBA/2 mice. The tendency to metastasize, as well as loss of the H-2Kk haplotype, appeared stable and irreversible. Although the precise origin of MDAY-D2 is not clear, its metastasizing properties are unique, making it a useful and desirable model to study the biology of metastasis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 721318     DOI: 10.1002/ijc.2910220513

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  30 in total

Review 1.  On the origin of cancer metastasis.

Authors:  Thomas N Seyfried; Leanne C Huysentruyt
Journal:  Crit Rev Oncog       Date:  2013

2.  Development of lymphosarcoma lines with high metastatic ability to lymph nodes and visceral organs in BALB/c mice.

Authors:  T Tsuruo; T Oh-Hara; T Yamori; S Tsukagoshi; T Ishikawa; H Sugano
Journal:  Clin Exp Metastasis       Date:  1988 Mar-Apr       Impact factor: 5.150

3.  Effect of hyperthermia and thermochemotherapy on primary and metastatic tumour cells of AKR lymphoma.

Authors:  G Klorin; A Siegal; B Bar-Shira-Maymon; O Klein; J Leibovici
Journal:  Int J Exp Pathol       Date:  1990-08       Impact factor: 1.925

4.  The ganglioside GD1 alpha' IV3Neu5Ac, III6Neu5Ac-GgOse4Cer, is a major disialoganglioside in the highly metastatic murine lymphoreticular tumour cell line MDAY-D2.

Authors:  J Müthing; J Peter-Katalinić; F G Hanisch; F Unland; J Lehmann
Journal:  Glycoconj J       Date:  1994-04       Impact factor: 2.916

Review 5.  Generation of phenotypic diversity and progression in metastatic tumor cells.

Authors:  G L Nicolson
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

6.  Melanoma x macrophage hybrids with enhanced metastatic potential.

Authors:  M Rachkovsky; S Sodi; A Chakraborty; Y Avissar; J Bolognia; J M McNiff; J Platt; D Bermudes; J Pawelek
Journal:  Clin Exp Metastasis       Date:  1998-05       Impact factor: 5.150

7.  Different biological behavior of AKR lymphoma cells from primary and metastatic tumors.

Authors:  J Leibovici; Y Stark; S Kopel
Journal:  Experientia       Date:  1985-03-15

8.  Sensitivity to thermochemotherapy of AKR lymphoma and B16 melanoma variants of malignancy.

Authors:  J Leibovici; G Klorin; M Huszar; S Hoenig; O Klein; M Michowitz; A Pinchassov
Journal:  Clin Exp Metastasis       Date:  1990 Jan-Feb       Impact factor: 5.150

Review 9.  Immunology of metastasis. Can the immune response cope with disseminated tumor?

Authors:  P Frost; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

10.  Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity.

Authors:  V Schirrmacher; R Heicappell
Journal:  Clin Exp Metastasis       Date:  1987 Apr-Jun       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.